In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTRL ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

Disclosed herein is a novel p53 complex and a collection of compounds that can tightly associate with p53 to efficiently rescue wildtype p53 structure and function, and the methods of making and using the complex and the compounds, including for diagnosis, prognosis, and treatment of p53 related disorders such as cancer and aging.

Disclosed herein is a novel p53 complex and a collection of compounds that can tightly associate with p53 to efficiently rescue wildtype p53 structure and function, and the methods of making and using the complex and the compounds, including for diagnosis, prognosis, and treatment of p53 related disorders such as cancer and aging.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient. Another objective of the present invention is to provide a topical, fixed-dose formulation containing a combination of antileishmanial compounds that has sufficient efficacy and safety to be used in the treatment of cutaneous leishmaniasis.

The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient. Another objective of the present invention is to provide a topical, fixed-dose formulation containing a combination of antileishmanial compounds that has sufficient efficacy and safety to be used in the treatment of cutaneous leishmaniasis.

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.